The use of plant miRNAs as adjuvants in cancer therapies has been already tested; for example, plant miR159, abundantly found in human serum, has been associated with reduced incidence and progression of breast cancer because it targets the TCF7 (a Wnt signaling transcription factor) gene, causing decreased levels of MYC (Avian Myelocytomatosis Viral Oncogene Homolog) proteins, essential for cell cycle progression (Chin et al., 2016). The gene discussed is TCF7; the disease is breast carcinoma.